Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

Long Islanders suffering from sleep apnea inundated the sleep center at St. Charles Hospital in Port Jefferson with phone ...

Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...

Eli Lilly (LLY) reports Q2 earnings on Aug 7, with booming diabetes and weight-loss drug sales driving strong growth.

When Eli Lilly reports its financial results early Thursday, investors will be looking for the company to press its advantage ...

This podcast was recorded on July 21, 2025. Tim Beyers: Is it time to buy biotech? You're listening to Motley Fool Money.

Novo, valued at $650 billion in June last year, has shed over two-thirds of its value since. Its latest market cap is around ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

The drugmaker released its second-quarter earnings report early Wednesday as it vowed to cut costs amid intensifying ...

Zepbound is a prescription drug used for weight management and obstructive sleep apnea. While depression was not reported in studies of Zepbound, it's still something to watch out for while using ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...